M&A Update – February 9

– NUVA to be acquired by GMED for 0.75x shares, 26.1% premium, $3.1 billion
– CSII to be acquired by ABT for $20.00 cash per share, 50.3% premium, $890 million
– FSTX / Sino Biopharmaceutical extended tender offer to Feb 22, negotiating definitive terms of such mitigation agreement in order to permit the removal of CFIUS’s Interim Order
– VLTA / SHEL filed PREM14a, no meeting date set, filed HSR Jan 25, filed French FDI Jan 31, closing H1 2023
– HCG.to shareholders approved acquisition by Smith Financial Corporation, closing mid 2023
– APEN vote